Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 6/2022

07-09-2021 | Abdominal Aortic Aneurysm | Original Article

HPMC improves protective effects of naringenin and isonicotinamide co-crystals against abdominal aortic aneurysm

Authors: Xing Zhang, Anyi Wang, Xiaotong Yang, Yunxia Wang, Qinyu Wang, Rui Hu, Gulinigaer Anwaier, Chang Di, Rong Qi, Yanbin Huang

Published in: Cardiovascular Drugs and Therapy | Issue 6/2022

Login to get access

Abstract

Purpose

Abdominal aortic aneurysm (AAA) rupture is one of the most common causes of mortality in cardiovascular diseases, but currently there is no approved drug for AAA treatment or prevention in the clinic. Naringenin (NGN) has been reported to have anti-AAA effects. However, water solubility and in vivo absorption of NGN are not satisfactory, which leads to its low bioavailability, thus affecting its pharmacological effects. In this project, the improving effects of isonicotinamide (INT) co-crystal and hydroxy propyl methyl cellulose (HPMC) or polyvinyl pyrrolidone (PVP) on the solubility, in vivo absorption, and anti-AAA effects of NGN were evaluated.

Methods

In the current study, co-crystals of naringenin-isonicotinamide (NGN-INT) were prepared, and effects of PVP or HPMC on precipitation rate, supersaturation, and bioavailability of NGN were explored. In addition, with or without HPMC supply, the effects of NGN-INT co-crystal on anti-AAA efficacy of NGN were investigated on an elastase-induced AAA mouse model, and the results were compared with the efficacy of the NGN crude drug.

Results

Our results demonstrate that NGN-INT formulation, compared to the NGN crude drug, enhanced the dissolution rate of NGN and significantly increased Cmax and AUC(0–∞) of NGN by 18 times and 1.97 times, respectively. Addition of PVP or HPMC in NGN-INT co-crystal further increased bioavailability of NGN in NGN-INT. The in vivo pharmacodynamic study showed that NGN-INT with HPMC significantly improved the inhibitory effects of NGN against AAA.

Conclusion

NGN-INT significantly improved the absorption and aortic protective effects of NGN. The supersaturation-prolonging effect of HPMC further enhanced bioavailability and anti-AAA effects of NGN-INT.

Graphical abstract

Literature
1.
Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN, Bandyk D, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med. 1997;126(6):441–9.CrossRefPubMed
2.
Alcorn HG, Wolfson SK, Sutton-Tyrrell K, Kuller LH, Oleary D. Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1996;16(8):963–70.CrossRefPubMed
3.
Tang L, Cong Z, Hao S, Li P, Huang H, Shen Y, et al. Protective effect of melatonin on the development of abdominal aortic aneurysm in a rat model. J Surg Res. 2017;209:266.CrossRefPubMed
4.
Htun NM, Peter K. Biomarkers for AAA: Encouraging steps but clinical relevance still to be delivered. Proteom Clin Appl. 2015;8(9-10):732–4.CrossRef
5.
Gillum RF. Epidemiology of aortic aneurysm in the United States. J Clin Epidemiol. 1995;48(11):1289–98.CrossRefPubMed
6.
Best VA, Price JF, Fowkes FGR. Persistent increase in the incidence of abdominal aortic aneurysm in Scotland, 1981-2000. Br J Surg. 2010;90(12):1510–5.CrossRef
7.
Liu Y. Study on the preparation method of naringenin. Chin J Spectr Lab. 2008;25(6):1292–4.
8.
Chen XF, Liu D, Li X. Study on supercritical CO2 extraction rocess of nagringenin from peach leaf. Food Sci. 2007;28(1):106–9.
9.
Liu WY, Huo P, Mei GQ, Xiong ZX, Wang RJ. The study on microwave synthesis and antibacterial activity of Hhesperetin aromatic hydrazone compounds. J Jiangxi Norm Univ. 2012;36(2):193–5.
10.
Chen Y, Nie YC, Luo YL, Lin F, Zheng YF, Cheng GH, et al. Protective effects of naringin against paraquat-induced acute lung injury and pulmonary fibrosis in mice. Food Chem Toxicol. 2013;58(4):133–40.CrossRefPubMed
11.
Kong W, Cui Q, Liu Z, Yu F, inventors; Use of naringenin in preparing drugs for preventing and/or treating abdominal aortic aneurysm. China patent WO 2014/206056 A1. 2014.12.31.
12.
Liang S, Zhou S, Yang S, Xia D, Wei Y, Gao Y, et al. Thermodynamic studies of naringenin-isonicotinamide cocrystals. Acta Pharm Sin. 2017;04:625–33.
13.
Cui WX, He ZH, Zhang YT, Fan QY, Feng NP. Naringenin cocrystals prepared by solution crystallization method for improving bioavailability and anti-hyperlipidemia effects. AAPS PharmSciTech. 2019;20(3):1–12.CrossRef
14.
Toth B. Lack of carcinogenicity of nicotinamide and isonicotinamide following lifelong administration to mice. Oncology. 1983;40(1):72–5.CrossRefPubMed
15.
Fukaya M, Tamura Y, Chiba Y, Tanioka T, Kaneki MJB. Protective effects of a nicotinamide derivative, isonicotinamide, against streptozotocin-induced β-cell damage and diabetes in mice. Biochem Biophys Res Commun. 2013;442(1–2).
16.
Rowe R, Sheskey P, Quinn M. Handbook of Pharmaceutical Excipients. 6th ed. London: Pharmaceutical Press; 2009.
17.
Zhang J, Xia D, Xu J, Gao Y, inventors; Naringenin isonicotinic acid eutectic. China patent CN 104817526 A. 2015.08.05.
18.
Sun DD, Wen H, Taylor LS. Non-sink dissolution conditions for predicting product quality and in vivo performance of supersaturating drug delivery systems. J Pharm Sci. 2016;105(9):2477–88.CrossRefPubMed
19.
Wang Y, Chen C, Wang Q, Cao Y, Xu L, Qi R. Inhibitory effects of cycloastragenol on abdominal aortic aneurysm and its related mechanisms. Br J Pharmacol. 2019;176(2):282–96.CrossRefPubMed
20.
Chen C, Jie X, Ou Y, Cao Y, Xu L, Wang Y, et al. Nanoliposome improves inhibitory effects of naringenin on nonalcoholic fatty liver disease in mice. Nanomedicine. 2017;12(15):1791–800.CrossRefPubMed
21.
Khan AW, Kotta S, Ansari SH, Sharma RK, Ali J. Enhanced dissolution and bioavailability of grapefruit flavonoid Naringenin by solid dispersion utilizing fourth generation carrier. Drug Dev Ind Pharm. 2015;41(5):772.CrossRefPubMed
22.
Ziller KH, Rupprecht H. Control of crystal growth in drug suspensions. Drug Dev Ind Pharm. 1988;14:2341–70.CrossRef
23.
Yang X, Shen B, Huang Y. Mechanistic study of HPMC-prolonged supersaturation of hydrocortisone. Cryst Growth Des. 2015;15(2):546–51.CrossRef
24.
Babu JN, Nangia A. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst Growth Des. 2011;11(7):2662–79.CrossRef
25.
Kuminek G, Cao F, Rocha ABDOD, Cardoso SG, Rodríguez-Hornedo N. Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5. Adv Drug Deliv Rev. 2016;101:143–66.CrossRefPubMedPubMedCentral
26.
Jasani MS, Kale DP, Singh IP, Bansal AK. Influence of drug-polymer interactions on dissolution of thermodynamically highly unstable cocrystal. Mol Pharm. 2019;16(1):151–64.CrossRefPubMed
27.
28.
Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65(1):315–499.CrossRefPubMed
29.
Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007;96:2686–702.CrossRefPubMed
30.
Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability. J Pharm Sci. 2009;98:2549–72.CrossRefPubMed
31.
Gao P, Morozowich W. Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs. Expert Opin Drug Del. 2006;3:97–110.CrossRef
32.
Bao L, Zhu J, Li Z. Effect of intraperitoneal fluid replacement on diarrhea in piglets. Agr Equip Tech. 2012;5:35–6.
Metadata
Title
HPMC improves protective effects of naringenin and isonicotinamide co-crystals against abdominal aortic aneurysm
Authors
Xing Zhang
Anyi Wang
Xiaotong Yang
Yunxia Wang
Qinyu Wang
Rui Hu
Gulinigaer Anwaier
Chang Di
Rong Qi
Yanbin Huang
Publication date
07-09-2021
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 6/2022
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-021-07206-x

Other articles of this Issue 6/2022

Cardiovascular Drugs and Therapy 6/2022 Go to the issue

Original Article

The Prognostic Impact of Anti-thrombotic Treatment Strategies After Biological Aortic Valve Replacement

Original Article

Influence of Moxonidine and Bisoprolol on Morphofunctional Condition of Arterial Wall and Telomerase Activity in Postmenopausal Women with Arterial Hypertension and Osteopenia. The Results from a Moscow Randomized Study

Letter to the Editor

Pharmacologic Cardioversion of Paroxysmal Atrial Fibrillation in the Emergency Department in the Novel Anticoagulants’ Era

Invited Review Article

Do We Really Need Aspirin Loading for STEMI?

Letter to the Editor

Reassessment of Confidence in a Network Meta-analysis of Antidysrhythmic Drugs for Atrial Fibrillation Cardioversion

Letter to the Editor

The application of proton pump inhibitors in cardiovascular disease needs to be individualized

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits